» Articles » PMID: 27605853

A Retrospective Review of Cryoprecipitate Transfusion Practice in Kuala Lumpur Hospital

Overview
Specialty Hematology
Date 2016 Sep 9
PMID 27605853
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cryoprecipitate is generally used to treat bleeding patients with hypofibrinogenemia, and the transfusion decision is guided based on published guidelines.

Aim: This study aimed to evaluate the practice appropriateness in accordance to cryoprecipitate transfusion guidelines in Hospital Kuala Lumpur.

Methodology: This cross-sectional study of 117 cryoprecipitates transfused adult patients was conducted in Kuala Lumpur Hospital from January to June 2012. The compliance of the indication of cryoprecipitate was considered as appropriate if indicated for patients who have hypofibrinogenemia (<1.0 g/L) with bleeding, or otherwise inappropriate if pretransfusion fibrinogen level was more than 1.0 g/L, pretransfusion fibrinogen level was not examined and posttransfusion fibrinogen level more than 1.5 g/L.

Results: Most of the cryoprecipitate prescriptions were found to be inappropriate, which read 81.2% (95% confidence interval = 0.740, 0.880). Patients who underwent neurovascular surgery were the major recipient of cryoprecipitate, but majority of the prescription was found not appropriate. The decision to transfuse cryoprecipitate was found mostly appropriate when was guided by fibrinogen (52.2%), but the percentage dropped to 10.6% when pretransfusion fibrinogen test was not performed. Regrettably, only 19.7% of total cryoprecipitate were given based on pretransfusion fibrinogen level.

Citing Articles

Cell Attachment Capacity and Compounds of Fibrin Membranes Isolated from Fresh Frozen Plasma and Cryoprecipitate.

Hinsenkamp A, Kun K, Gajnut F, Majer A, Lacza Z, Hornyak I Membranes (Basel). 2021; 11(10).

PMID: 34677549 PMC: 8541203. DOI: 10.3390/membranes11100783.

References
1.
Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz R, Bouvier-Colle M . Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth. 2012; 108(6):984-9. DOI: 10.1093/bja/aes096. View

2.
. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA. 1994; 271(10):777-81. View

3.
Callum J, Karkouti K, Lin Y . Cryoprecipitate: the current state of knowledge. Transfus Med Rev. 2009; 23(3):177-88. DOI: 10.1016/j.tmrv.2009.03.001. View

4.
Yazer M, Triulzi D, Hassett A, Kiss J . Cryoprecipitate prepared from plasma frozen within 24 hours after phlebotomy contains acceptable levels of fibrinogen and VIIIC. Transfusion. 2009; 50(5):1014-8. DOI: 10.1111/j.1537-2995.2009.02535.x. View

5.
Bennett E, DORMANDY K . Pool's cryoprecipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-XI deficiency. Lancet. 1966; 2(7466):731-2. DOI: 10.1016/s0140-6736(66)92985-0. View